Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209

Pathological T0 Following Cisplatin-Based Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Network Meta-analysis

“…In particular, chemo-induced tumor downstaging is considered to be a useful and potential surrogate marker that has been associated with favorable survival outcomes among patients treated with subsequent RC (11,(13)(14)(15)(16). The impact of various NACH regimens including CM, CMV, MVAC, and GC, on the achievement of pCR and on survival outcomes has been evaluated by many investigators, both retrospectively and prospectively (14,(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33). There was only one prospective trial that evaluated the CMV (31) and CM (32) regimens.…”

“…There was only one prospective trial that evaluated the CMV (31) and CM (32) regimens. The survival benefit achieved with the NACH with MVAC regimen in patients with MIBC was prospectively assessed in several phase III studies (14,30,33), and MVAC has been considered to be an effective regimen in a neoadjuvant setting. Although the GC regimen has not been studied in a prospective setting, it has been the most commonly used and acceptable alternative to MAVC in clinical practices based on the results of several retrospective comparative studies that were conducted in patients with locally advanced bladder cancer (18,19,21,22,25,26,28 In the current meta-analysis, we aimed to determine which type of NACH regimen was optimal in terms of pCR achievement among patients with MIBC who underwent subsequent RC.…”

“…A total of 1,238 articles were excluded on the basis of the titles and abstracts, and the full-text versions of 99 articles were evaluated. In accordance with the inclusion criteria, a final selection of 17 articles was performed (14,(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33) and any discrepancies were resolved. A PRISMA flowchart depicting the process for the systematic literature search and selection of the studies is shown in Fig.…”

“…The studies were published between 1994 and 2014, and patients were recruited between 1986 and 2013. Five studies were prospective randomized trials (14,(30)(31)(32)(33). Additional characteristics of the eligible studies are summarized in Table 1.…”

Preoperative sarcopenia status is associated with lymphovascular invasion in upper tract urothelial carcinoma patients treated with radical nephroureterectomy

“…[22][23][24] Since UTUC is the same histological type of UC, neoadjuvant chemotherapy for UTUC is expected to be effective. 25 Martin et al previously showed that neoadjuvant chemotherapy achieved significant pathological downstaging and complete remission in 14% of UTUC surgical specimens.…”